Intravitreal anti-vascular endothelial growth factor medications during pregnancy: current perspective.
Morteza NaderanMasomeh SabzevaryKeivan RezaiiAli BanafshehafshanSeddigheh HantoushzadehPublished in: International ophthalmology (2020)
Women of childbearing age should be consulted regarding the potential adverse effects of anti-VEGF medications on fetal health and the risk of early pregnancy loss. They should be strongly encouraged to use appropriate contraceptive methods during treatment. A timely obstetrics consultation may help in this situation. Attempt for pregnancy should be withheld for at least 3 months following last injection of ranibizumab and aflibercept, and for at least 6 months following last injection of bevacizumab.
Keyphrases
- vascular endothelial growth factor
- endothelial cells
- age related macular degeneration
- pregnancy outcomes
- healthcare
- ultrasound guided
- public health
- palliative care
- polycystic ovary syndrome
- mental health
- preterm birth
- type diabetes
- human health
- adipose tissue
- insulin resistance
- adverse drug
- skeletal muscle
- metastatic colorectal cancer
- metabolic syndrome
- climate change